Associations between vitamin D and disease risk may be attributed to
the confounding influence of adiposity during childhood and adulthood:
a lifecourse Mendelian randomization study
Tom G Richardson ^{1,2*} , Grace M Power ¹ , George Davey Smith ¹
¹ MRC Integrative Epidemiology Unit (IEU), Population Health Sciences, Bristol Medical School, University of
Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, United Kingdom
² Novo Nordisk Research Centre, Headington, Oxford, OX3 7FZ, United Kingdom
Running title: Time-varying effects of adiposity on vitamin D levels
Keywords: Mendelian randomization, Lifecourse epidemiology, Childhood adiposity,
Vitamin D, ALSPAC
Word count: 1,078
Total number of figures and tables: 1

20 Abstract

21 Background: Vitamin D supplements are widely prescribed to help reduce disease risk.

- 22 However, this strategy is based on findings using conventional epidemiological methods
- 23 which are prone to confounding and reverse causation.
- 24 Methods: In this short report, we leveraged genetic variants which differentially influence
- 25 body size during childhood and adulthood within a multivariable Mendelian randomization
- 26 (MR) framework, allowing us to separate the genetically predicted effects of adiposity at
- 27 these two timepoints in the lifecourse.
- 28 **Results:** Using data from the Avon Longitudinal Study of Parents and Children (ALSPAC),
- 29 there was strong evidence that higher childhood body size has a direct effect on lower
- 30 vitamin D levels in early life (mean age: 9.9 years, range=8.9 to 11.5 years) after accounting
- 31 for the effect of the adult body size genetic score (Beta=-0.32, 95% CI=-0.54 to -0.10,
- 32 P=0.004). Conversely, we found evidence that the effect of childhood body size on vitamin
- 33 D levels in midlife (mean age: 56.5 years, range=40 to 69 years) is putatively mediated
- 34 along the causal pathway involving adulthood adiposity (Beta=-0.17, 95% CI=-0.21 to -0.13,
- 35 P=4.6x10⁻¹⁷).
- 36 Conclusions: Our findings have important clinical implications in terms of the causal 37 influence of vitamin D deficiency on disease risk. Furthermore, they serve as a compelling 38 proof of concept that the timepoints across the lifecourse at which exposures and outcomes 39 are measured can meaningfully impact overall conclusions drawn by MR studies.
- 40 Funding: This work was supported by the Integrative Epidemiology Unit which receives
 41 funding from the UK Medical Research Council and the University of Bristol
 42 (MC UU 00011/1).
- 43

44 Introduction

45 Associations between vitamin D deficiency and disease risk have been widely reported by 46 conventional epidemiological studies, including diseases which typically have a late-onset 47 over the lifecourse, such as coronary artery disease, but also those which may be diagnosed 48 in early life such as type 1 diabetes (T1D). As a result, vitamin D supplements are widely 49 prescribed with an estimated 18% of adults in the USA reportedly taking supplements daily 50 (Rooney *et al.*, 2017). However, there is increasing evidence from the literature suggesting 51 that vitamin D supplements may be ineffective at reducing disease risk in the population 52 (Murai *et al.*, 2021), and although there are notable exceptions (e.g. multiple sclerosis 53 (Mokry *et al.*, 2015, Vandebergh *et al.*, 2022)), this raises uncertainty into the causal effects 54 of vitamin D levels on many disease outcomes. Furthermore, these conventional 55 associational studies may have been susceptible to bias, given that vitamin D levels are 56 known to differ amongst individuals based on various lifestyle factors, including their body 57 mass index (BMI), as well as being prone to reverse causation, for example due to 58 inflammatory processes which are known to lower vitamin D levels (Preiss and Sattar, 59 2019).

60

61 An approach to mitigate the influence of these sources of bias is Mendelian randomization 62 (MR), a causal inference technique which exploits the random allocation of genetic variants 63 at birth to evaluate the genetically predicted effects of modifiable exposures on disease 64 outcomes and circulating biomarkers (Davey Smith and Ebrahim, 2003, Richmond and 65 Davey Smith, 2022). For example, MR has been applied in recent years to suggest that 66 vitamin D supplements are unlikely to have a beneficial effect on risk of type 1 diabetes 67 (Manousaki et al., 2021). We previously extended the application of MR to investigate 68 epidemiological hypotheses in lifecourse setting (known to as 'lifecourse MR'), by deriving 69 sets of genetic variants to separate the independent effects of body size during childhood 70 and adulthood within a multivariable framework (Richardson *et al.*, 2020). Applying this 71 approach has highlighted the putative causal role that early life adiposity may have on 72 outcomes such as T1D risk (Richardson et al., 2022) and cardiac structure (O'Nunain et al 73 (in press)). In contrast, we have demonstrated that it's influence on other disease outcomes

(e.g. cardiovascular disease (Power *et al.*, 2021)) is likely attributed to the long-term consequence of remaining overweight into later life. Whilst these applications serve as powerful examples of lifecourse MR as an approach to separate the effects of the same exposure based on data derived from early and later life, it has yet to be applied to the same outcome when measured at different timepoints in the lifecourse.

79

80 **Results**

81 In this study, we applied lifecourse MR to investigate the independent effects of childhood 82 and adult body size has a largely indirect influence on 25-hydroxyvitamin D (250HD) levels measured during childhood (mean age: 9.9 years, range=8.9 to 11.5 years) using 83 84 individual-level data from the Avon Longitudinal Study of Parents and Children (ALSPAC) 85 (Boyd et al., 2013, Fraser et al., 2013) and during adulthood (mean age: 56.5 years, 86 range=40 to 69 years) using summary-level data based on individuals from the UK Biobank 87 (UKB) study (Manousaki et al., 2020). Firstly, using data derived from the ALSPAC study, 88 our analyses indicated that childhood body size directly influences vitamin D levels during 89 childhood after accounting for the adult body size genetic instrument in our model (Beta=-90 0.32 standard deviation (SD) change in natural log-transformed 250HD per change in body 91 size category, 95% CI=-0.54 to -0.10, P=0.004) (Figure 1A & Figure 1B). Using data from 92 the UKB study, evidence of an effect of higher childhood body size on adulthood measured 250HD levels (Beta=-0.14, 95% CI=-0.10 to -0.03, P=2.4x10⁻⁴) attenuated in a multivariate 93 94 setting upon accounting for adulthood body size (Beta=0.04, 95% CI=-0.01 to 0.08, P=0.10). In contrast, strong evidence of an effect for higher adult body size on lower 250HD levels 95 measured in adulthood was found in the multivariable model (Beta=-0.17, 95% CI=-0.21 to 96 97 -0.13, P=4.6x10⁻¹⁷) (**Figure 1C**). This suggests that childhood body size has an indirect 98 influence of 250HD levels in adulthood, likely due to its persistent effect throughout the 99 lifecourse (Figure 1D).

100

101 **Figure 1**





103

A) A forest plot illustrating the direct effect of childhood body size on circulating vitamin D levels measured during childhood (mean age: 9.9 years) using participant data from the Avon Longitudinal Study of Parents and Children (ALSPAC) with the corresponding schematic diagram for this finding being located in panel B). C) A forest plot depicting the indirect effect of childhood body size on adulthood measured vitamin D levels using data from the UK Biobank study (mean age: X years) as described in the schematic diagram presented in panel D). MR – Mendelian randomization.

109

110 **Discussion**

Our findings suggest that increased adiposity exerts a strong effect on lower vitamin D 111 112 levels during both childhood and adulthood. Separating causal from confounding factors, 113 particularly in a lifecourse setting, would have been extremely challenging to disentangle 114 without the use of genetic variants as achieved in this study. In contrast, appropriately 115 accounting for confounding factors in an conventional epidemiological setting is 116 notoriously challenging, with previous studies reporting evidence of association between 117 vitamin D and T1D in early life even after adjusting for factors such as birthweight 118 (Hypponen *et al.*, 2001). Taken together with evidence from previous MR studies, which 119 have found that childhood body size (Richardson *et al.*, 2022), but not vitamin D levels 120 (Manousaki et al., 2021), increases risk of T1D, our results suggest that adiposity may have 121 acted as a confounding factor on the observed association between vitamin D and T1D. 122 These findings therefore have important clinical implications in terms of whether patients 123 newly diagnosed with T1D should be prescribed vitamin D supplements or not.

124

125 Effect estimates derived from MR studies are conventionally interpreted as 'lifelong effects' 126 given that the germline genetic variants harnessed by this approach as instrumental 127 variables are typically fixed at conception. The results of this study serve as a compelling 128 demonstration that the timepoint at which both exposures and outcomes are measured 129 across the lifecourse can meaningfully impact conclusions drawn by MR investigations. 130 Whilst the childhood and adult body size genetic scores were used in this study as a proof 131 of concept, our findings also help to further validate their utility in separating the temporal 132 effects of adiposity within a lifecourse MR framework. Overall, these findings emphasise 133 the importance of future MR studies taking further consideration into the age of 134 participants that their genetic estimates are based on, as well as the age at which cases are 135 diagnosed for disease outcome estimates, before interpreting and drawing conclusions 136 from their findings. Furthermore, our results highlight the importance of conducting 137 genome-wide association studies on populations of different age groups to help uncover 138 time-varying genetic effects scattered throughout the human genome. Findings from these 139 endeavours should facilitate insight into the direct and indirect effects of modifiable early

140 life exposures using approaches such as lifecourse MR. This may help to elucidate the 141 critical timepoints whereby conferred risk by these exposures on disease outcomes starts 142 to become immutable, which has important implications for improving patient care in a 143 clinical setting.

144 Materials and Methods

145 ALSPAC is a population-based cohort investigating genetic and environmental factors that 146 affect the health and development of children. The study methods are described in detail 147 elsewhere (Boyd et al., 2013, Fraser et al., 2013). In brief, 14,541 pregnant women 148 residents in the former region of Avon, UK, with an expected delivery date between April 1, 149 1991 and December 31, 1992, were eligible to take part in ALSPAC. Detailed phenotypic 150 information, biological samples and genetic data which have been collected from the 151 ALSPAC participants are available through a searchable data dictionary (http:// 152 www.bris.ac.uk/alspac/researchers/our-data/). Written informed consent was obtained 153 for all study participants. Ethical approval for this study was obtained from the ALSPAC 154 Ethics and Law Committee and the Local Research Ethics Committees. Measures of 25-155 hydroxyvitamin D (250HD) levels were obtained from non-fasting blood samples taken 156 from ALSPAC participants at mean age 9.9 years (range=8.9 to 11.5 years) which were log 157 transformed to ensure normality.

158

159 Derivation of genetic instruments for childhood and adulthood body size have been 160 described in detail previously (Richardson et al., 2020). In brief, genome-wide association 161 studies (GWAS) were conducted on 463,005 UK Biobank (UKB) participants (mean age: 162 56.5 years, range=40 to 69 years) who had both reported their body size at age 10 as well 163 as had their BMI clinically measured. Genetic instruments were identified from these 164 analyses (based on $P < 5x10^{-8}$) and the resulting genetic score for childhood body size has 165 been validated using measured childhood BMI in ALSPAC (Richardson et al., 2020), the Young Finns Study (Richardson et al., 2021) and the Trøndelag Health (HUNT) study 166 167 (Brandkvist et al., 2020). Genetic estimates on adulthood 250HD were obtained from a 168 previously conducted GWAS in UKB (Manousaki *et al.*, 2020). Despite having overlapping 169 samples when analysing our body size instruments against the adulthood measure of

- vitamin D, there was little evidence of inflated type 1 error rates (based on the calculator at
 https://sb452.shinyapps.io/overlap) (Burgess *et al.*, 2016).
- 172

173 Mendelian randomization (MR) analyses to estimate genetically predicted effects on 174 childhood 250HD were conducted in a one-sample setting using individual level data from 175 ALSPAC after generating genetic risk scores for our body size instruments with adjustment 176 for age and sex. MR analyses to estimate effects on adulthood 250HD were undertaken in a 177 two-sample setting using the inverse variance weighted (IVW) method (Burgess et al., 178 2013), as this allowed us to additionally perform analyses using the weighted median and 179 MR-Egger methods (Bowden et al., 2015, Bowden et al., 2016). (Supplementary Table 1). 180 Multivariable MR were performed in one- and two-sample settings respectively for 181 childhood and adulthood measures of 250HD (Sanderson et al., 2019) (Supplementary

182 183 Table 2).

184 Data availability

- 185 All individual level data analysed in this study can be accessed via an approved application
- 186 to ALSPAC (http://www.bristol.ac.uk/alspac/researchers/access/). Summary-level data on
- 187 adulthood vitamin D levels can be accessed publicly via the OpenGWAS
- 188 (<u>https://gwas.mrcieu.ac.uk/</u>).

189 **Consent**

- 190 Written informed consent was obtained for all study participants. Ethical approval for this
- 191 study was obtained from the ALSPAC Ethics and Law Committee and the Local Research
- 192 Ethics Committees.

193 Competing Interests

194 TGR is employed part-time by Novo Nordisk outside of this work. All other authors declare195 no conflicts of interest.

196 **Funding**

- 197 This work was supported by the Integrative Epidemiology Unit which receives funding
- 198 from the UK Medical Research Council and the University of Bristol (MC_UU_00011/1).

199 Acknowledgements

200 We are extremely grateful to all the families who took part in this study, the midwives for 201 their help in recruiting them and the whole ALSPAC team, which includes interviewers, 202 computer and laboratory technicians, clerical workers, research scientists, volunteers, 203 managers, receptionists and nurses. The UK Medical Research Council and Wellcome 204 (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. 205 Consent for biological samples has been collected in accordance with the Human Tissue Act 206 (2004). GWAS data was generated by Sample Logistics and Genotyping Facilities at 207 Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using 208 support from 23andMe.

209

- 210 This research was conducted at the NIHR Biomedical Research Centre at the University
- 211 Hospitals Bristol NHS Foundation Trust and the University of Bristol. The views expressed
- in this publication are those of the author(s) and not necessarily those of the NHS, the
- 213 National Institute for Health Research or the Department of Health. This publication is the
- 214 work of the authors and TGR will serve as guarantor for the contents of this paper.

215 **References**

- 216 Bowden, J., Davey Smith, G. & Burgess, S. 2015. Mendelian randomization with invalid
- instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol*, 44,
 512-25.
- 219 Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. 2016. Consistent Estimation in
- Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator.
 Genet Epidemiol, 40, 304-14.
- 222 Boyd, A., Golding, J., Macleod, J., Lawlor, D. A., Fraser, A., Henderson, J., Molloy, L., Ness,
- A., Ring, S. & Davey Smith, G. 2013. Cohort Profile: the 'children of the 90s'--the index
- offspring of the Avon Longitudinal Study of Parents and Children. Int J Epidemiol, 42, 111-27.
- 225 Brandkvist, M., Bjorngaard, J. H., Odegard, R. A., Asvold, B. O., Smith, G. D., Brumpton, B.,
- 226 Hveem, K., Richardson, T. G. & Vie, G. A. 2020. Separating the genetics of childhood and adult
- 227 obesity: a validation study of genetic scores for body mass index in adolescence and adulthood in
- the HUNT Study. *Hum Mol Genet*.
- 229 Burgess, S., Butterworth, A. & Thompson, S. G. 2013. Mendelian randomization analysis with
- 230 multiple genetic variants using summarized data. *Genet Epidemiol*, 37, 658-65.
- 231 Burgess, S., Davies, N. M. & Thompson, S. G. 2016. Bias due to participant overlap in two-
- sample Mendelian randomization. *Genet Epidemiol*, 40, 597-608.
- 233 Davey Smith, G. & Ebrahim, S. 2003. 'Mendelian randomization': can genetic epidemiology
- contribute to understanding environmental determinants of disease? Int J Epidemiol, 32, 1-22.
- 235 Fraser, A., Macdonald-Wallis, C., Tilling, K., Boyd, A., Golding, J., Davey Smith, G.,
- Henderson, J., Macleod, J., Molloy, L., Ness, A., Ring, S., Nelson, S. M. & Lawlor, D. A. 2013.
- 237 Cohort Profile: the Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort.
- 238 Int J Epidemiol, 42, 97-110.
- 239 Hypponen, E., Laara, E., Reunanen, A., Jarvelin, M. R. & Virtanen, S. M. 2001. Intake of
- vitamin D and risk of type 1 diabetes: a birth-cohort study. *Lancet*, 358, 1500-3.
- 241 Manousaki, D., Harroud, A., Mitchell, R. E., Ross, S., Forgetta, V., Timpson, N. J., Smith, G. D.,
- 242 Polychronakos, C. & Richards, J. B. 2021. Vitamin D levels and risk of type 1 diabetes: A
- 243 Mendelian randomization study. *PLoS Med*, 18, e1003536.
- 244 Manousaki, D., Mitchell, R., Dudding, T., Haworth, S., Harroud, A., Forgetta, V., Shah, R. L.,
- 245 Luan, J., Langenberg, C., Timpson, N. J. & Richards, J. B. 2020. Genome-wide Association
- 246 Study for Vitamin D Levels Reveals 69 Independent Loci. Am J Hum Genet, 106, 327-337.
- 247 Mokry, L. E., Ross, S., Ahmad, O. S., Forgetta, V., Smith, G. D., Goltzman, D., Leong, A.,
- 248 Greenwood, C. M., Thanassoulis, G. & Richards, J. B. 2015. Vitamin D and Risk of Multiple
- 249 Sclerosis: A Mendelian Randomization Study. *PLoS Med*, 12, e1001866.
- 250 Murai, I. H., Fernandes, A. L., Sales, L. P., Pinto, A. J., Goessler, K. F., Duran, C. S. C., Silva,
- 251 C. B. R., Franco, A. S., Macedo, M. B., Dalmolin, H. H. H., Baggio, J., Balbi, G. G. M., Reis, B.

- 252 Z., Antonangelo, L., Caparbo, V. F., Gualano, B. & Pereira, R. M. R. 2021. Effect of a Single
- 253 High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe
- 254 COVID-19: A Randomized Clinical Trial. JAMA, 325, 1053-1060.
- 255 Power, G. M., Tyrrell, J., Frayling, T. M., Davey Smith, G. & Richardson, T. G. 2021.
- 256 Mendelian Randomization Analyses Suggest Childhood Body Size Indirectly Influences End
- 257 Points From Across the Cardiovascular Disease Spectrum Through Adult Body Size. J Am Heart 258 Assoc, 10, e021503.
- 259 Preiss, D. & Sattar, N. 2019. Research digest: vitamin D supplementation. Lancet Diabetes
- 260 Endocrinol, 7, 91.
- 261 Richardson, T. G., Crouch, D. J. M., Power, G. M., Berstein, F. M., Hazelwood, E., Fang, S.,
- 262 Cho, Y., Inshaw, J. R. J., Robertson, C. C., Sidore, C., Cucca, F., Rich, S. S., Todd, J. A. &
- 263 Smith, G. D. 2022. Childhood body size directly increases type 1 diabetes risk based on a 264 lifecourse Mendelian randomization approach. Nat Commun (in press).
- 265 Richardson, T. G., Mykkanen, J., Pahkala, K., Ala-Korpela, M., Bell, J. A., Taylor, K., Viikari,
- 266 J., Lehtimaki, T., Raitakari, O. & Davey Smith, G. 2021. Evaluating the direct effects of
- 267 childhood adiposity on adult systemic metabolism: a multivariable Mendelian randomization
- 268 analysis. Int J Epidemiol.
- 269 Richardson, T. G., Sanderson, E., Elsworth, B., Tilling, K. & Davey Smith, G. 2020. Use of
- 270 genetic variation to separate the effects of early and later life adiposity on disease risk:
- 271 mendelian randomisation study. BMJ, 369, m1203.
- 272 Richmond, R. C. & Davey Smith, G. 2022. Mendelian Randomization: Concepts and Scope.
- 273 Cold Spring Harb Perspect Med, 12.
- 274 Rooney, M. R., Harnack, L., Michos, E. D., Ogilvie, R. P., Sempos, C. T. & Lutsey, P. L. 2017.
- 275 Trends in Use of High-Dose Vitamin D Supplements Exceeding 1000 or 4000 International
- 276 Units Daily, 1999-2014. JAMA, 317, 2448-2450.
- 277 Sanderson, E., Davey Smith, G., Windmeijer, F. & Bowden, J. 2019. An examination of
- 278 multivariable Mendelian randomization in the single-sample and two-sample summary data
- 279 settings. Int J Epidemiol, 48, 713-727.
- 280 Vandebergh, M., Degryse, N., Dubois, B. & Goris, A. 2022. Environmental risk factors in
- 281 multiple sclerosis: bridging Mendelian randomization and observational studies. J Neurol.
- 282
- 283